JAMA Rejected Comment to Abella et al.

HCWs taking HCQ for prophylaxis are more likely to expose themselves to COVID-19

Effectiveness of Hydroxychloroquine as preexposure prophylaxis against COVID-19 is well established. The normal regimen is 1,000-2,000 mg over 3-5 days, followed by 200-400 mg weekly

In [1], the necessary concentration of HCQ metabolites was achieved only after 4 weeks. After that, the HCQ group had 80% lower rate of sickness than the control group.

HCWs can distinguish between placebo and HCQ. The same study notes that healthcare workers taking HCQ for prophylaxis are likely to take more risks of COVID-19 exposure than not taking it.


[1] Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, Singh H, Praharaj I, Gangakhedkar RR, Bhargava B, Panda S. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res 2020;151:459-67. http://www.ijmr.org.in/text.asp?2020/151/5/459/285520



Dear Leo Goldstein,
Thank you for submitting your online comment to JAMA Internal Medicine.
We have decided not to publish it. Our commenting policy reviews some of the reasons we choose not to publish submitted comments.
We are nevertheless grateful for your interest in JAMA Internal Medicine.
Thank you,
The Editors

Leave a Reply

Your email address will not be published. Required fields are marked *